AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30986790 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD‐TDV (Dengvaxia) booster dose
Number of subjects: 251
Study 30986790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 28494809 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise and dietary therapy (PED-t) for 16 weeks
Number of subjects: 0
Study 28494809 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT) for 16 weeks
Number of subjects: 0
Study 28494809 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study 25881915 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain insertion (group A)
Number of subjects: 193
Study 25881915 — intervention group
Group type: COMPARATOR
Intervention: No drain insertion (group B)
Number of subjects: 193
Study 25881915 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 193
Study 24399727 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose metformin (3 g daily in three divided doses)
Number of subjects: 43
Study 24399727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 21272195 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 80 mg
Number of subjects: 1275
Study 21272195 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 40 mg
Number of subjects: 1275
Study 21272195 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan medoxomil 40 mg
Number of subjects: 1275
Study 21272195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1275
Study 18285726 — intervention group
Group type: EXPERIMENTAL
Intervention: KATEX method for antigen detection in urine
Number of subjects: 132
Study 16956341 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosiplex, 50 mg/kg daily per os for 12 weeks
Number of subjects: 38
Study 16956341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 16956341 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosiplex
Number of subjects: 38
Study 12648031 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10-80 mg/day)
Number of subjects: 3887
Study 12648031 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin (20-40 mg/day, or 40 mg twice daily)
Number of subjects: 3887
Study 12648031 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin (20-40 mg/day, or 40 mg twice daily)
Number of subjects: 3887
Study 12648031 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (10-40 mg/day)
Number of subjects: 3887
Study 12648031 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (10-40 mg/day)
Number of subjects: 3887
Study 10638663 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 50 mg/kg body weight in 5% dextrose
Number of subjects: 36
Study 10638663 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 50 mg/kg + rutin 5 mg/kg in 5% dextrose
Number of subjects: 36
Study 10638663 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose in water (control group)
Number of subjects: 36
Study 9402073 — intervention group
Group type: COMPARATOR
Intervention: HIV vaccine intervention
Number of subjects: 48
Study 1550667 — intervention group
Group type: EXPERIMENTAL
Intervention: Office blood pressure measurements (referring doctors)
Number of subjects: 159
Study 1550667 — intervention group
Group type: EXPERIMENTAL
Intervention: Random zero office measurements
Number of subjects: 159
Study 1550667 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime ambulatory blood pressures
Number of subjects: 159
Study 1550667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory monitoring
Number of subjects: 159
Study 1550667 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference between systolic office measurements and daytime ambulatory blood pressures
Number of subjects: 159
Study 1550667 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic measurements
Number of subjects: 159
Study 3965439 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of haloperidol
Number of subjects: 6
Study 3965439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of haloperidol
Number of subjects: 6
Study 29353384 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care training (12 sessions)
Number of subjects: 60
Study 29353384 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 60
Study 28833331 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenicriviroc (CVC) 150 mg
Number of subjects: 289
Study 28833331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 26778661 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training + Creatine supplementation (CREATINE, n = 10)
Number of subjects: 30
Study 26778661 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training + Placebo (PLACEBO, n = 10)
Number of subjects: 30
Study 26778661 — intervention group
Group type: COMPARATOR
Intervention: Control group (CONTROL, n = 10)
Number of subjects: 30
Study 24957544 — intervention group
Group type: EXPERIMENTAL
Intervention: 32-hour training course as HIV prevention peer educators
Number of subjects: 182
Study 24957544 — intervention group
Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 182
Study 22414319 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 week exercise programme of 12 × 60 minutes of preferred intensity aerobic exercise with motivational coaching and support
Number of subjects: 158
Study 22414319 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 158
Study 20589253 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental plaque-free samples (GI)
Number of subjects: 13
Study 20589253 — intervention group
Group type: COMPARATOR
Intervention: Dental plaque-covered samples (GII)
Number of subjects: 13
Study 17888803 — intervention group
Group type: EXPERIMENTAL
Intervention: CALM intervention (education and behavioral activation delivered by anxiety clinical specialists, with options for cognitive-behavioral therapy, antianxiety medications, or both)
Number of subjects: 1040
Study 17888803 — intervention group
Group type: COMPARATOR
Intervention: Usual care from primary care clinician
Number of subjects: 1040
Study 15142360 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine (T4) plus slow-release triiodothyronine (T3)
Number of subjects: 0
Study 15142360 — intervention group
Group type: COMPARATOR
Intervention: Thyroxine (T4) only
Number of subjects: 0
Study 11784215 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 504
Study 11784215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 504
Study 9660534 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron plus methylprednisolone (250 mg i.v. twice daily)
Number of subjects: 308
Study 9660534 — intervention group
Group type: COMPARATOR
Intervention: Granisetron alone (3 mg i.v. over 30 s)
Number of subjects: 308
Study 8704424 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhong Feng I oral liquor (acute stage), Zhong Feng II oral liquor (convalescent stage) and Western medicine
Number of subjects: 120
Study 8704424 — intervention group
Group type: COMPARATOR
Intervention: Western medicine alone
Number of subjects: 120
Study 2515723 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl 10 mg per day
Number of subjects: 800
Study 2515723 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocopherol 2000 IU per day
Number of subjects: 800
Study 2515723 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl plus Tocopherol
Number of subjects: 800
Study 2515723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 649844 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 dB tone with active response
Number of subjects: 96
Study 649844 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 dB tone with passive escape contingency
Number of subjects: 96
Study 649844 — intervention group
Group type: EXPERIMENTAL
Intervention: Inescapable tone
Number of subjects: 96
Study 649844 — intervention group
Group type: COMPARATOR
Intervention: No noise (control group)
Number of subjects: 96
Study 31830798 — intervention group
Group type: EXPERIMENTAL
Intervention: Making Your Wishes Known, a values‐neutral, educational, computer‐based decision aid
Number of subjects: 200
Study 31830798 — intervention group
Group type: COMPARATOR
Intervention: Standard living will + brochure
Number of subjects: 200
Study 30922751 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Number of subjects: 114
Study 30922751 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 114
Study 30922751 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group (light resistance training)
Number of subjects: 114
Study 28835364 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based growth monitoring (HBGM)
Number of subjects: 547
Study 28835364 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based growth monitoring with nutritional supplementation (CBGM+NS)
Number of subjects: 547
Study 28835364 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 547
Study 26262764 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered-shaped cuff (TSC)
Number of subjects: 98
Study 26262764 — intervention group
Group type: COMPARATOR
Intervention: Cylindrical-shaped cuff (CSC)
Number of subjects: 98
Study 24791510 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of small needle knife and Daqinjiu Tang
Number of subjects: 118
Study 24791510 — intervention group
Group type: COMPARATOR
Intervention: Small needle knife
Number of subjects: 118
Study 21330911 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC with Remune
Number of subjects: 52
Study 21330911 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC alone
Number of subjects: 52
Study 21330911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 21330911 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC with Remune and ALVAC alone (combined vaccine groups)
Number of subjects: 52
Study 19011261 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% oxygen
Number of subjects: 131
Study 19011261 — intervention group
Group type: COMPARATOR
Intervention: 21% air
Number of subjects: 131
Study 16077745 — intervention group
Group type: EXPERIMENTAL
Intervention: New enteral formula low in carbohydrates and high in monounsaturated fatty acids (MUFAs)
Number of subjects: 78
Study 16077745 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral formula (control)
Number of subjects: 78
Study 16077745 — intervention group
Group type: EXPERIMENTAL
Intervention: New enteral formula low in carbohydrates and high in MUFAs
Number of subjects: 78
Study 11833404 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip strength measured via a dynamometer and pinch strength via a pinch meter.
Number of subjects: 51
Study 10577644 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone
Number of subjects: 0
Study 10577644 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 7560619 — intervention group
Group type: COMPARATOR
Intervention: Balloon Angioplasty
Number of subjects: 1012
Study 7560619 — intervention group
Group type: COMPARATOR
Intervention: Directional Atherectomy
Number of subjects: 1012
Study 7560619 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral Vascular Complications
Number of subjects: 1012
Study 7560619 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Peripheral Vascular Complications
Number of subjects: 1012
Study 2140432 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 145
Study 2140432 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 145
Study 2140432 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS plus exercises
Number of subjects: 145
Study 2140432 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS plus exercises
Number of subjects: 145
Study 2140432 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise groups
Number of subjects: 145
Study 2140432 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise groups
Number of subjects: 145
Study 7004956 — intervention group
Group type: EXPERIMENTAL
Intervention: Dantrolene sodium suspension
Number of subjects: 20
Study 7004956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30353603 — intervention group
Group type: EXPERIMENTAL
Intervention: Musical training (weekly 45-min lessons for 52 weeks)
Number of subjects: 60
Study 30353603 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 60
Study 28747269 — intervention group
Group type: EXPERIMENTAL
Intervention: 4HIIT (4×4min bouts at 85-95%HRpeak, 3×/week)
Number of subjects: 56
Study 28747269 — intervention group
Group type: EXPERIMENTAL
Intervention: MICT (30min at 60-70%HRpeak, 5×/week)
Number of subjects: 56
Study 28747269 — intervention group
Group type: EXPERIMENTAL
Intervention: 1HIIT (1×4min bout at 85-95%HRpeak, 3×/week)
Number of subjects: 56
Study 26479077 — intervention group
Group type: EXPERIMENTAL
Intervention: Health risk assessment (HRA) and counselling over a 2-year period.
Number of subjects: 2284
Study 24036724 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan (group 1)
Number of subjects: 76
Study 24036724 — intervention group
Group type: COMPARATOR
Intervention: No CT scan (group 2)
Number of subjects: 76
Study 21225098 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dabigatran 220 mg once-daily
Number of subjects: 2055
Study 21225098 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous enoxaparin 40 mg once-daily
Number of subjects: 2055
Study 19137352 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylan G-F 20
Number of subjects: 33
Study 19137352 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (Control)
Number of subjects: 33
Study 17356145 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy extracorporeal shock-wave therapy
Number of subjects: 80
Study 17356145 — intervention group
Group type: COMPARATOR
Intervention: Low-energy extracorporeal shock-wave therapy
Number of subjects: 80
Study 15359161 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide diameter implants (5.0 and 6.0 mm)
Number of subjects: 106
Study 15359161 — intervention group
Group type: COMPARATOR
Intervention: Standard diameter implants (3.75 and 4.0 mm)
Number of subjects: 106
Study 15359161 — intervention group
Group type: EXPERIMENTAL
Intervention: Torque driver used to tighten screws
Number of subjects: 106
Study 11123735 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine, 4 microg x kg(‐1)
Number of subjects: 60
Study 11123735 — intervention group
Group type: COMPARATOR
Intervention: Diazepam, 0.4 mg x kg(‐1)
Number of subjects: 60
Study 9720821 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (100 microg)
Number of subjects: 12
Study 7989502 — intervention group
Group type: EXPERIMENTAL
Intervention: Onapristone 5 mg/day
Number of subjects: 7
Study 7989502 — intervention group
Group type: EXPERIMENTAL
Intervention: Onapristone 15 mg/day
Number of subjects: 7
Study 7989502 — intervention group
Group type: EXPERIMENTAL
Intervention: Onapristone 50 mg/day
Number of subjects: 7
Study 7989502 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment (after discontinuation of onapristone)
Number of subjects: 7
Study 7989502 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase post-treatment
Number of subjects: 7
Study 7989502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol concentrations
Number of subjects: 7
Study 7989502 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious side effects
Number of subjects: 7
Study 2658875 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino-hydroxypropylidene bisphosphonate (APD)
Number of subjects: 40
Study 2658875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 5579489 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual withdrawal of anticholinergic drugs over four weeks
Number of subjects: 34
Study 5579489 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt withdrawal of anticholinergic drugs
Number of subjects: 34
Study 5579489 — intervention group
Group type: COMPARATOR
Intervention: Stable levodopa therapy with anticholinergic drugs
Number of subjects: 34
Study 29747321 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower risk group (SYNTAX score≤22)
Number of subjects: 2348
Study 29747321 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate risk group (SYNTAX score 23‐32)
Number of subjects: 2348
Study 29747321 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher risk group (SYNTAX score≥33)
Number of subjects: 2348
Study 28264826 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-determined dosage of insulin (CDD) using the STAR-GRYPHON model
Number of subjects: 138
Study 28264826 — intervention group
Group type: COMPARATOR
Intervention: Bedside titration: insulin dose determined by medical staff
Number of subjects: 138
Study 28264826 — intervention group
Group type: COMPARATOR
Intervention: Standard care: insulin dose and frequency of blood glucose testing determined by medical staff
Number of subjects: 138
Study 25742886 — intervention group
Group type: EXPERIMENTAL
Intervention: Physioneal
Number of subjects: 45
Study 25742886 — intervention group
Group type: COMPARATOR
Intervention: Dianeal
Number of subjects: 45
Study 25742886 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study 23206182 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine monotherapy
Number of subjects: 0
Study 23206182 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine combination therapy
Number of subjects: 0
Study 23206182 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine in combination therapy
Number of subjects: 0
Study 21244204 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills group intervention
Number of subjects: 0
Study 21244204 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18489804 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise group
Number of subjects: 26
Study 18489804 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education control group
Number of subjects: 26
Study 16572592 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 16572592 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors
Number of subjects: 0
Study 16572592 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (Herceptin)
Number of subjects: 0
Study 12736476 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteroseptal myocardial infarction (MI) group
Number of subjects: 61
Study 12736476 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 12736476 — intervention group
Group type: EXPERIMENTAL
Intervention: MI group
Number of subjects: 61
Study 10540063 — intervention group
Group type: EXPERIMENTAL
Intervention: Latex balloon pressure controller
Number of subjects: 0
Study 10540063 — intervention group
Group type: COMPARATOR
Intervention: Standard tracheal tube cuff without controller
Number of subjects: 0
Study 8569424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg orally each evening for 1 week
Number of subjects: 8
Study 8569424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 8
Study 1910730 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative and postoperative steroid use
Number of subjects: 49
Study 6121581 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 50
Study 6121581 — intervention group
Group type: COMPARATOR
Intervention: Dummy tablets (control)
Number of subjects: 50
Study 31519527 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial variables (including religiosity, knowledge regarding blood donation process, overall quality of life, blood donation of peers, sociodemographic variables, fear of blood, injections, and fainting)
Number of subjects: 1055
Study 28447237 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 492
Study 28447237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 492
Study 26422096 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 5 or 10 mg once daily
Number of subjects: 31
Study 23319135 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinofibrate 200mg
Number of subjects: 0
Study 23319135 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinofibrate 400mg
Number of subjects: 0
Study 23319135 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinofibrate 600mg
Number of subjects: 0
Study 23319135 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinofibrate (all doses)
Number of subjects: 0
Study 21881066 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor (PI)-based HAART
Number of subjects: 40
Study 21881066 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnucleoside reverse transcriptase inhibitor-based HAART (without PI)
Number of subjects: 40
Study 21881066 — intervention group
Group type: COMPARATOR
Intervention: Control group (HIV-negative participants)
Number of subjects: 40
Study 19118720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg/day
Number of subjects: 62
Study 19118720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 17446306 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (200 mg tid for 3 weeks)
Number of subjects: 26
Study 17446306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 15132449 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonding with Equalized Specific Thickness (BEST) technique
Number of subjects: 41
Study 15132449 — intervention group
Group type: COMPARATOR
Intervention: Transfer Optimized Positioning (TOP) method
Number of subjects: 41
Study 11824173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 628
Study 11824173 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone
Number of subjects: 628
Study 11824173 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 628
Study 11104592 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative gastric supply of nutrients (Osmolite, Ross; first 3 hours 30 ml/h and second 3 hours 50 ml/h; total 240 ml after 6 hours)
Number of subjects: 80